Role of FOXO3A in trastuzumab combination chemotherapy in esophageal squamous cell carcinoma

Masashi Takahashi, Kazumasa Fukuda, Yoshiro Saikawa, Rieko Nakamura, Norihito Wada, Hirofumi Kawakubo, Hiroya Takeuchi, Yuko Kitagawa

研究成果: Article査読

抄録

Background/Aim: Targeting of the human epidermal growth factor receptor 2 (HER2) is suggested to be beneficial for esophageal squamous cell carcinoma (ESCC) patients with HER2 amplification. In this study, we evaluated the effects of combination chemotherapy with HER2-targeted drug trastuzumab in ESCC cells and examined the underlying mechanism contributing to these effects. Materials and Methods: HER2 expression was verified, and the efficacy of chemotherapy with and without trastuzumab was investigated in vitro and in vivo. Results: The combination of trastuzumab and a combined-modality therapy stimulated the PI3K/Akt pathway in ESCC cells overexpressing HER2. Trastuzumab treatment resulted in the intranuclear accumulation of FOXO3A in ESCC xenografts overexpressing HER2. The combination of trastuzumab and a combined-modality therapy enhanced antitumor effects in HER2-overexpressing ESCC xenografts. Conclusion: FOXO3A plays an important role in mediating the effects of trastuzumab, and combination chemotherapy may be a promising treatment for patients with HER2-overexpressing ESCC.

本文言語English
ページ(範囲)1921-1930
ページ数10
ジャーナルAnticancer research
40
4
DOI
出版ステータスPublished - 2020 4

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

フィンガープリント 「Role of FOXO3A in trastuzumab combination chemotherapy in esophageal squamous cell carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル